evipedia.ai
← Back

Nattokinase for Health & Longevity

Evidence Review created on 10/13/2026 using AI4L / Opus 5.5

Also known as: NK, Subtilisin NAT, Natto Enzyme, Fermented Soybean Extract, NSK-SD

Motivation

Nattokinase is an enzyme made by a bacterium when it ferments soybeans into natto, a sticky traditional Japanese food. Purified and sold as an oral supplement, it attracts interest because it can break down the protein mesh that holds blood clots together, which raises the prospect of keeping blood flowing freely into older age without a prescription drug.

Natto has been eaten in Japan for centuries, and the enzyme itself was identified in the 1980s by a Japanese researcher screening foods for clot-dissolving activity. Since then it has been studied for blood pressure, the health of artery walls, and blood clotting, and it has become a popular supplement among people looking for a food-derived way to support heart and blood vessel health as they age.

This review examines the human evidence on nattokinase as a long-term supplement for health and longevity: what it may do for blood pressure, blood vessels, and clotting; how strong and how independent that evidence is; what bleeding and drug-combination risks it carries; and how it is used in practice.

Benefits - Risks - Protocol - Conclusion

Expert commentary and narrative reviews that give a high-level overview of nattokinase, its proposed uses, and its limits.

No item from the priority experts is listed except Life Extension. Rhonda Patrick’s only dedicated discussion (FoundMyFitness Q&A #80, April 2026) is a members-only episode that cannot be read publicly, so it cannot be linked or verified. Searches of the sites of Peter Attia, Andrew Huberman, Chris Kresser, and Lifespan.io found no article or episode that discusses nattokinase in depth, only passing mentions or no results.

Grokipedia

Nattokinase

AI-generated encyclopedia entry covering the enzyme’s origin, structure, proposed clot-dissolving and blood-pressure actions, clinical studies, safety, and regulation; useful for orientation, though its claims need checking against the primary studies.

Examine

Nattokinase

Independent evidence summary with dosing information (most commonly 2,000 units of clot-dissolving activity daily), graded study outcomes for blood pressure and cholesterol, and question-and-answer entries on absorption and bleeding likelihood.

ConsumerLab

Nattokinase Supplements Review

Independent laboratory testing of eight nattokinase products, of which only five passed; the members-only report also covers clinical evidence, dosage, side effects, allergic reactions, and drug interactions.

Systematic Reviews

This section lists the only systematic review and meta-analysis (a statistical pooling of several studies) of nattokinase found on PubMed.

No systematic review or meta-analysis has assessed the principal risk of nattokinase, bleeding, so that side of the trade-off is unrepresented in this section.

Mechanism of Action

Nattokinase is a serine protease (an enzyme that cuts other proteins) produced by Bacillus subtilis var. natto. Its proposed actions are:

  • Direct clot breakdown: it digests fibrin (the protein mesh of clots) and mimics the action of plasmin (the body’s own clot-dissolving enzyme) (Sumi 1987).
  • Releasing the brakes on clot breakdown: in laboratory work it cleaves and inactivates PAI-1 (plasminogen activator inhibitor-1, a protein that blocks clot dissolution), strengthening the effect of tPA (tissue plasminogen activator, the enzyme that switches on plasmin) (Urano 2001).
  • Lower clotting proteins: in an uncontrolled human study, fibrinogen (the precursor of fibrin) and clotting factors VII and VIII fell (Hsia 2009).
  • Blood flow and pressure: it reduced red blood cell clumping and blood thickness in test tubes (Pais 2006) and lowered renin activity (a kidney enzyme that starts a blood-pressure-raising cascade) in a trial co-authored by Japan Bio Science Laboratory staff (Kim 2008).

The competing view questions absorption of so large a protein: it crossed the gut in rats (Fujita 1995), but the EU authorization notes clot-dissolving activity in test-tube studies and in animals given it by injection (Commission Implementing Decision (EU) 2017/115).

Pharmacology: no true half-life has been measured; enzyme-like material in human blood peaked about 13 hours after an oral dose (Ero 2013). It is not selective: it also digests unrelated proteins in laboratory work (Hsu 2009); tissue distribution is unknown. As a protein it is degraded by protein-digesting enzymes, not CYP enzymes (cytochrome P450, the liver’s drug-metabolizing enzymes).

Historical Context & Evolution

Natto has been a Japanese food for more than a thousand years (Pais 2006); its original use was simply nourishment. In 1987, Hiroyuki Sumi reported a strong fibrinolytic (clot-dissolving) activity in natto and named the enzyme nattokinase (Sumi 1987). That discovery, together with Japan’s long life expectancy, turned a food component into a candidate supplement for circulation.

Japanese producers developed purified extracts, some with vitamin K2 (a form of vitamin K made by natto bacteria that counteracts the blood thinner warfarin) removed. Small Asian and North American trials in 2008–2016 reported lower blood pressure (Kim 2008), while a Japanese cohort (a long-term population study) linked natto-food intake to lower cardiovascular death (Nagata 2017). The European Commission authorized one extract as a novel food (a food requiring safety approval because it lacked a history of significant EU consumption) in 2017, capped at 100 mg daily (Commission Implementing Decision (EU) 2017/115).

Opinion then split along dose lines. The NAPS (Nattokinase Atherothrombotic Prevention Study), a 3-year randomized controlled trial (RCT, a study that assigns participants to treatment or placebo by chance) at 2,000 FU (fibrinolytic units, the standard activity measure) daily, found no slowing of artery-wall thickening (Hodis 2021). A Chinese group, co-authoring with staff of the tablet maker Sungen Bioscience, then reported plaque and cholesterol reductions at 10,800 FU in an uncontrolled study (Chen 2022). No placebo-controlled high-dose trial has yet tested which reading holds.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: no trial has measured heart attack, stroke, or death with the purified enzyme, and the validated surrogate with replicated data, blood pressure, rests on small 8-week trials contradicted by the largest trial.

Medium 🟩 🟩

Lower Blood Pressure ⚠️ Conflicted

In adults with mildly raised pressure, two 8-week placebo-controlled trials, Kim in Korea (Kim 2008) and Jensen in North America (Jensen 2016, sponsored by its US distributor), lowered it at 2,000 FU daily; a six-trial meta-analysis agreed (Li 2023). The 3-year NAPS trial in low-risk adults (Hodis 2021) and a 4-week crossover trial (each participant took both products in turn) with nattokinase as the comparison (Hitosugi 2015) found no effect. Graded Medium: positive trials are small, short, manufacturer-linked. Net reading: a modest reduction is likely only when pressure is raised.

Magnitude: Systolic (upper) pressure 5.55 mmHg lower than placebo (95% CI, confidence interval, the range likely to contain the true effect: −10.5 to −0.57) and diastolic (lower) pressure 2.84 mmHg lower (95% CI −5.33 to −0.33) after 8 weeks (Kim 2008); pooled across trials, systolic 3.45 mmHg lower than placebo (95% CI −4.37 to −2.18) (Li 2023).

Better Recovery After Ischemic Stroke

In a Vietnamese trial by Pham and colleagues, 61 adults in the months after an ischemic stroke (a stroke caused by a blocked brain artery) took Nattospes capsules providing 1,200 FU of nattokinase daily, or placebo, alongside rehabilitation with electroacupuncture and intravenous piracetam (a drug given to support brain recovery) for 60 days (Pham 2020). The nattokinase group scored better on disability, neurological, and daily-living scales. Graded Medium as a single small trial in which the treating doctors knew group assignment; it has not been repeated.

Magnitude: Better scores than placebo after 60 days on the modified Rankin scale (a disability rating), the Orgogozo scale (a neurological deficit score), and the Barthel index (a measure of independence in daily activities), between-group P ≤ .01 (P, the probability that a difference this large would arise by chance alone); the article’s text reports no between-group outcome figure (Pham 2020).

Low 🟩

In the LONFLIT-FLITE trial by Cesarone and Belcaro, high-risk passengers on 7–8-hour flights taking Flite Tabs, a combination of nattokinase and pine bark extract, had fewer ultrasound-detected deep vein thromboses (clots in deep leg veins) (Cesarone 2003). Graded Low as indirect: two agents were combined, and blinding was unclear.

Magnitude: No deep vein clots in 94 treated passengers versus 5 of 92 (5.4%) on placebo; counting dropouts as failures, 7.4% versus 19.6% (Cesarone 2003).

Relief of Venous Disease Symptoms

In an Italian series of 153 vascular-surgery patients, nattokinase 100 mg daily for 30 days, given after courses of the injectable blood thinners fondaparinux or enoxaparin or after vein surgery, was followed by complete symptom remission (Gallelli 2021). Graded Low: there was no control group, and nattokinase followed other treatments.

Magnitude: Complete symptom remission after 30 days of nattokinase in all three patient groups (no control group) (Gallelli 2021).

Slower Carotid Plaque Growth ⚠️ Conflicted

A retrospective study of 1,062 Chinese adults, mostly on 10,800 FU daily for a year, reported thinner carotid (main neck artery) walls and smaller plaques; 61 on 3,600 FU showed none (Chen 2022). The randomized NAPS trial at 2,000 FU found no effect (Hodis 2021). Net reading: unproven, possibly dose-dependent.

Magnitude: Mean carotid intima-media thickness (thickness of the inner artery wall layers) fell from 1.33 to 1.04 mm over 12 months (no control group) (Chen 2022; a corrigendum corrected only the baseline table and does not change this figure); in NAPS, wall thickening was 0.013 mm per year on nattokinase versus 0.011 mm per year on placebo, not significantly different (NAPS results).

Lower Blood Cholesterol ⚠️ Conflicted

High-dose studies from one Chinese group reported lower total and LDL (low-density lipoprotein, “bad”) cholesterol at 6,000 FU, less than simvastatin (Ren 2017), and at 10,800 FU uncontrolled (Chen 2022). Lower-dose placebo-controlled trials found no benefit (Li 2023, Yang 2009). Net reading: no reliable benefit at usual doses.

Magnitude: Pooled low-dose trials: total cholesterol 5.27 higher than placebo (95% CI 3.74 to 6.81) (Li 2023); at 10,800 FU, total cholesterol fell 15.9% and LDL cholesterol 18.1% over 12 months (no control group) (Chen 2022).

Lower Cardiovascular Death (Natto Food)

In the Takayama cohort of 29,079 Japanese adults followed for 16 years, the highest natto intake was linked to lower cardiovascular death (Nagata 2017). Graded Low as indirect: natto food also supplies vitamin K2, fiber, and soy compounds, unlike the purified enzyme.

Magnitude: HR (hazard ratio, the relative rate of death over time) 0.75 (95% CI 0.64 to 0.88) for total cardiovascular death, top versus bottom quarter of natto intake (Nagata 2017).

Protection of Thinking Skills ⚠️ Conflicted

In NAPS, global cognition changed identically on nattokinase and placebo over 3 years (NAPS results). The ICC-PACS trial (8,000 FU for 6 months in narrowed head or neck arteries) found no global benefit, only an exploratory gain in visuospatial (spatial reasoning) skills (Zhang 2026). Net reading: no demonstrated benefit.

Magnitude: Global cognition score rose by 0.43 standard units in both arms, not compared between groups in the posted record (NAPS results); Montreal Cognitive Assessment change differed by 0.038 points versus placebo (95% CI −1.109 to 1.163) (Zhang 2026).

Speculative 🟨

Faster Clot Breakdown in Blood Tests ⚠️ Conflicted

Small trials found raised clot-breakdown products and longer clotting times (Kurosawa 2015; Yoo 2019, with a nattokinase-maker co-author); 3-year NAPS found no change (Hodis 2021). These markers are unvalidated. Net reading: inconsistent.

Breakdown of Amyloid Deposits

Nattokinase digested amyloid fibrils (protein clumps seen in Alzheimer’s disease) in test tubes (Hsu 2009) and reduced plaque in a rat model (Tanikawa 2024, co-authored by commercial-firm staff). Basis is laboratory and animal only.

Degradation of Coronavirus Spike Protein

In cell experiments co-authored by commercial-firm staff, nattokinase degraded spike protein (the COVID-19 virus’s entry protein) (Tanikawa 2022); a post-COVID regimen by a supplement-company shareholder builds on this (Hulscher 2023). Basis is laboratory only.

Better Peripheral Blood Flow ⚠️ Conflicted

A single 2,000 FU dose sped finger rewarming after cold-water immersion (Nara 2023); as the comparison product, 4 weeks of nattokinase left limb coldness unchanged (Hitosugi 2015). Net reading: unproven; skin temperature is unvalidated.

Benefit-Modifying Factors

  • Genetic variants: In laboratory tests on 1,796 human blood samples, clot-dissolving speed varied with ABO and Rh blood group and with age (Bhatt 2026); no trial has confirmed this. NAPS registered an APOE4 (a gene variant raising Alzheimer’s risk) analysis, still unreported (NAPS record).
  • Baseline blood pressure: Reductions appeared in people starting at systolic 130–159 mmHg (Kim 2008), but not in the largely low-risk NAPS population with normal pressure (Hodis 2021).
  • Baseline renin: Among participants with low starting renin activity, 66% shifted upward toward normal on nattokinase versus 8% on placebo, a non-significant trend (P<0.1) hinting that renin status shapes response (Jensen 2016).
  • Baseline lipids: Cholesterol changes were reported only in people with raised lipids taking high doses (Chen 2022); placebo-controlled lower-dose trials showed none (Li 2023).
  • Sex: Blood pressure fell more robustly in men, while von Willebrand factor (a clotting protein linked to cardiovascular risk) fell only in women, as a non-significant trend (Jensen 2016).
  • Pre-existing conditions: Larger lipid and carotid changes were reported in obese participants, smokers, and drinkers, who started with worse values (uncontrolled data) (Chen 2022).
  • Age: NAPS (median age 65) found no benefit at 2,000 FU (Hodis 2021); the high-dose study (ages 63–85) reported benefits without a control group (Chen 2022). No trial has analyzed age as a modifier.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: the serious harms come from case reports, and the only pooled laboratory signal rests on a single meta-analysis contradicted by the longest trial.

Medium 🟥 🟥

Small Rise in Blood Glucose ⚠️ Conflicted

A meta-analysis of six placebo-controlled trials found slightly higher blood glucose on nattokinase than on placebo, with no mechanism proposed (Li 2023). The 3-year NAPS trial, included in that pooling, reported no effect on any laboratory measure (Hodis 2021). Graded Medium because the signal rests on one pooled analysis of small trials. Net reading: a small glucose rise is possible; its clinical relevance is unknown.

Magnitude: Blood glucose 0.40 higher than placebo (95% CI 0.20 to 0.60), pooled across trials (Li 2023).

Low 🟥

Serious Bleeding ⚠️ Conflicted

Case reports describe a cerebellar hemorrhage (brain bleed) in an aspirin user with cerebral microbleeds (tiny old brain bleeds) (Chang 2008) and a fatal abdominal bleed in a 92-year-old taking large self-doses (Ramachandran 2021). NAPS found none (Hodis 2021). Net reading: rare, with aspirin co-use or very high doses.

Magnitude: No serious bleeding event in either arm over 3 years; serious adverse events in 13 of 132 on nattokinase versus 15 of 133 on placebo; minor bleeding or bruising events 7 (2 nosebleeds, 2 vaginal bleeds, 1 rectal bleed, 2 contusions, i.e., bruises) versus 5 on placebo (gum bleeding, bloody stool, a contusion, a haematoma, i.e., a pooled collection of blood under the skin, a bruising tendency) (NAPS results).

Clot Formation When Replacing Prescribed Anticoagulants

A patient with a mechanical aortic valve who replaced warfarin with nattokinase for nearly a year developed a clot on the valve and needed repeat valve surgery (Elahi 2015). The harm stems from losing proven anticoagulation, not from nattokinase itself.

Magnitude: Not quantified in available studies. Only a single case report exists, so no rate can be estimated.

Allergic Reactions

Anaphylaxis (a severe whole-body allergic reaction) from nattokinase occurred in a patient with natto allergy (Awatani-Yoshidome 2022), and nattokinase was identified as a natto allergen (Suzuki 2023). Natto’s sticky coating is another allergen, with sensitization linked mainly to surfing (Inomata 2018). Graded Low: case reports and clinic series only.

Magnitude: Not quantified in available studies. No trial of purified nattokinase has reported an allergic reaction; the evidence is case reports and small clinic series without a comparison group, and the EU judged the extract’s allergy risk similar to other soy products (Commission Implementing Decision (EU) 2017/115).

Speculative 🟨

Excessive Blood Pressure Lowering

Adding nattokinase to blood pressure medication could lower pressure further, given the modest reductions seen in trials. No cases of low blood pressure have been reported; basis is mechanistic only.

Risk-Modifying Factors

  • Inherited bleeding disorders: Conditions such as von Willebrand disease (an inherited shortage of a clotting protein) or hemophilia add to nattokinase’s anticlotting effect. No gene variant affecting nattokinase handling is known.
  • Baseline clotting tests: A prolonged aPTT (activated partial thromboplastin time, a clotting-speed test), raised PT/INR (prothrombin time/international normalized ratio, a standardized clotting test), or low platelets signal higher risk; nattokinase prolonged aPTT in a trial (Yoo 2019).
  • Sex: No sex difference in bleeding has been shown. In NAPS, vaginal bleeding occurred in 2 postmenopausal women on nattokinase versus none on placebo (NAPS results).
  • Brain and gut conditions: Cerebral microbleeds, prior brain hemorrhage, or peptic ulcer (stomach or duodenal ulcer) raise bleeding risk; the reported brain bleed occurred in a patient with microbleeds taking aspirin (Chang 2008).
  • Conditions needing anticoagulation: Mechanical heart valves, atrial fibrillation (an irregular heart rhythm that causes clots), or past deep vein thrombosis carry clot risk if nattokinase replaces prescribed therapy (Elahi 2015).
  • Kidney and liver disease: Reduced kidney or liver function impairs clotting balance; NAPS excluded people with serum creatinine (a kidney-function blood marker) above 2.0 mg/dL (NAPS record).
  • Older age: The fatal abdominal bleed occurred in a 92-year-old (Ramachandran 2021); microbleeds, multiple medications, and falls, which raise bleeding risk, are more common in older adults.
  • Soy or natto allergy: Prior soy or natto allergy raises the chance of an allergic reaction; NAPS excluded people with soy allergy (NAPS record).

Key Interactions & Contraindications

  • Anticoagulants (warfarin, apixaban, rivaroxaban, dabigatran, enoxaparin): Caution, use only under medical supervision; additive bleeding risk (theoretical). A real-world series starting nattokinase after fondaparinux or enoxaparin courses, not alongside them, reported no adverse reactions (Gallelli 2021); EU labels require supervision (Commission Implementing Decision (EU) 2017/115).
  • Warfarin with vitamin K2-containing products (natto food, combination supplements): Monitor INR; vitamin K2 lowered INR in volunteers on a warfarin-type drug, risking clots (Theuwissen 2013). The EU-authorized extract limits vitamin K2 to 0.1 mg/kg (Commission Implementing Decision (EU) 2017/115).
  • Antiplatelet drugs (drugs that stop platelets clumping; aspirin, clopidogrel, ticagrelor): Caution; additive bleeding. A brain bleed occurred with aspirin (Chang 2008); an uncontrolled cohort co-using aspirin recorded no adverse effects (Chen 2022). Avoid in people with microbleeds.
  • Thrombolytic (clot-busting) drugs (alteplase, tenecteplase): Avoid (theoretical); stacking clot-dissolving agents could cause serious bleeding. Supplement use is relevant information in emergency stroke or heart attack care.
  • Over-the-counter NSAIDs (nonsteroidal anti-inflammatory drugs: ibuprofen, naproxen, high-dose aspirin): Caution (theoretical); NSAIDs impair platelets and irritate the stomach lining, so combination may increase stomach or intestinal bleeding.
  • SSRIs (selective serotonin reuptake inhibitors, a class of antidepressants: sertraline, fluoxetine): Monitor (theoretical); SSRIs deplete platelet serotonin and modestly raise bleeding risk, which may add to nattokinase’s effect.
  • Antihypertensive (blood pressure-lowering) drugs (amlodipine, lisinopril, losartan): Monitor (theoretical); additive pressure lowering may cause dizziness or light-headedness on standing. Home readings in the first weeks reveal excess lowering.
  • Supplements with anticlotting effects (fish oil, vitamin E, ginkgo, garlic, curcumin): Caution (theoretical); additive bleeding tendency. Curcumin is combined with nattokinase in a proposed post-COVID regimen (Hulscher 2023).
  • Other fibrinolytic (clot-dissolving) enzymes (lumbrokinase, serrapeptase, bromelain): Caution (theoretical); overlapping clot-dissolving action may raise bleeding risk. Bromelain is part of the same proposed regimen (Hulscher 2023).
  • Blood-pressure-lowering supplements (garlic, beetroot nitrate, magnesium): Monitor (theoretical); additive lowering may cause dizziness.
  • Red yeast rice: Monitor; combination trials found larger lipid and blood pressure changes than nattokinase alone and no adverse events (Yang 2009; Liu 2024, co-authored by staff of the supplement company BYHEALTH).
  • Surgery and dental procedures: Caution; enhanced clot breakdown may increase procedural bleeding (theoretical). Pausing beforehand is common practice; no study defines the interval.

Populations who should avoid Nattokinase:

  • People taking prescribed anticoagulants or antiplatelet drugs without medical supervision (Commission Implementing Decision (EU) 2017/115)
  • People using it as a substitute for prescribed anticoagulation, such as after mechanical valve replacement (Elahi 2015)
  • People with bleeding disorders or bleeding tendencies (a NAPS exclusion) (NAPS record)
  • People with cerebral microbleeds or prior brain hemorrhage (Chang 2008)
  • Pregnant or breastfeeding women, and children (the EU authorization covers adults only, excluding pregnancy and lactation) (Commission Implementing Decision (EU) 2017/115)
  • People with soy or natto allergy (a NAPS exclusion) (NAPS record)
  • People with renal insufficiency (reduced kidney function), serum creatinine above 2.0 mg/dL (a NAPS exclusion) (NAPS record)

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Never replacing prescribed anticoagulants: Keeping warfarin or other prescribed therapy unchanged prevents the valve clot seen after self-substitution (Elahi 2015).
  • Supervised use with anticoagulant or antiplatelet drugs: Combining with anticoagulant or antiplatelet drugs only under a prescriber’s oversight, as the EU label requires for medication users (Commission Implementing Decision (EU) 2017/115), with INR or clotting checks, limits bleeding.
  • Staying within the best-studied dose: 2,000 FU (100 mg) daily has 3 years of placebo-controlled safety data (Hodis 2021); higher doses lack it. This limits unknown bleeding risk.
  • Pausing before procedures: Stopping about 7 days before surgery, dental extraction, or joint or spinal injections, and resuming once bleeding risk has passed, reduces procedural bleeding.
  • Vitamin K2-free products on warfarin: Extracts labeled K2-free (as NSK-SD is) prevent weakening of warfarin’s effect and the resulting clot risk.
  • Baseline clotting screen: PT/INR, aPTT, and platelet checks before starting, for those over 60, on anticoagulant or antiplatelet drugs, or with a bleeding history, detect a hidden bleeding tendency.
  • Watching for bleeding signs: Stopping and seeking medical review for black stools, blood in urine, unusual bruising, or sudden severe headache catches serious bleeding early.
  • Home blood pressure checks: Weekly readings for the first month, when blood pressure medication is also taken, prevent dizziness or falls from excess lowering.
  • Avoidance with soy or natto allergy: Not using nattokinase when allergic to soy or natto prevents allergic reactions, including anaphylaxis.
  • Limiting supplement stacking: Not combining several other anticlotting supplements (fish oil, ginkgo, lumbrokinase) at once reduces additive bleeding risk.

Therapeutic Protocol

Each dose below is cited to its source; timing, splitting, cycling, and other parameters without a citation reflect common practice.

  • Standard dose (2,000 FU daily): One 100 mg capsule of 2,000 FU, as in the blood pressure trial (Kim 2008) and NAPS (Hodis 2021); the EU caps the authorized extract at 100 mg daily (Commission Implementing Decision (EU) 2017/115).
  • High-dose approach (6,000–10,800 FU daily): A Chinese group used 6,000 FU (Ren 2017) and 10,800 FU as three 3,600 FU tablets (Chen 2022) for plaque and cholesterol, without placebo-controlled safety data.
  • Post-COVID regimen: Peter McCullough’s protocol uses 2,000 FU twice daily with bromelain and curcumin for 3–12 months (Hulscher 2023); it is untested in controlled trials.
  • Long-haul travel: The flight trial used Flite Tabs (nattokinase plus pine bark) (Cesarone 2003), taken 2 hours before departure and again 6 hours later (Makar, Life Extension).
  • Popularizers: Hiroyuki Sumi, the discoverer, and Japan Bio Science Laboratory, maker of NSK-SD, promoted the purified enzyme; physician Ralph Holsworth advocated combining it with low-dose warfarin, which Clot Connect, whose author consulted for rivaroxaban makers, criticized (Clot Connect).
  • Time of day: Commonly taken in the evening on an empty stomach; no trial compared timings. After a single dose, clot-breakdown markers rose within 2–8 hours (Kurosawa 2015).
  • Half-life: No true half-life has been measured; enzyme-like material in blood peaked about 13 hours after a 2,000 FU dose and was detectable from 2 to 24 hours (Ero 2013).
  • Single versus split doses: 2,000 FU is usually taken once daily; higher totals used multiple units, 2 × 2,000 FU capsules (Hsia 2009) or 3 × 3,600 FU tablets (Chen 2022) daily; splitting across the day is untested.
  • Genetic factors: No pharmacogenetic variant guides dosing; an APOE4 analysis was planned in NAPS but has not been reported (NAPS record).
  • Sex differences: Blood pressure fell more in men, and von Willebrand factor trended down only in women (Jensen 2016); no sex-specific dosing exists.
  • Age: Trials enrolled older adults (NAPS median 65 (Hodis 2021); high-dose study ages 63–85 (Chen 2022)); the higher bleeding consequences in older age favor the best-studied 2,000 FU dose.
  • Baseline biomarkers: Blood pressure response was seen with starting systolic 130–159 mmHg (Kim 2008); lipid changes only with raised cholesterol at high dose (Chen 2022).
  • Pre-existing conditions: People with hypertension are the best-studied responders; those on anticoagulant or antiplatelet drugs, with microbleeds, or with bleeding disorders carry the highest bleeding risk (Chang 2008).

Discontinuation & Cycling

  • Duration: Used long term for cardiovascular aims (3 years in NAPS (Hodis 2021), 12 months in the high-dose study (Chen 2022)), for a single day around long flights, or 3–12 months in the post-COVID regimen (Hulscher 2023).
  • Withdrawal effects: None reported. Single-dose laboratory changes were measured only up to 8 hours (Kurosawa 2015), and no rebound clotting after stopping has been described.
  • Tapering: Not needed; abrupt stopping is common practice, as nattokinase does not suppress any natural body process that must recover.
  • Cycling: No evidence that cycling maintains efficacy; all trials used continuous daily dosing, and no tolerance to the enzyme has been reported.
  • Planned pauses: Stopping before surgery or dental procedures is the main reason to interrupt use; resumption follows once bleeding risk has passed (common practice).

Sourcing and Quality

  • Activity in FU, not milligrams: Potency depends on fibrinolytic activity, so a label stating FU is the meaningful measure; in 2025 ConsumerLab testing, only 5 of 8 products passed (ConsumerLab).
  • Standardized extract: The EU-authorized extract is a fermented soybean extract from Japan Bio Science Laboratory, maker of NSK-SD (Clot Connect), standardized to 20,000–28,000 FU per gram with tested limits for heavy metals and microbes (Commission Implementing Decision (EU) 2017/115).
  • Vitamin K2 removal: Purified extracts usually remove the vitamin K2 present in natto; the EU-authorized extract allows no more than 0.1 mg/kg, which matters for warfarin users (Commission Implementing Decision (EU) 2017/115).
  • Third-party testing: Independent verification of FU activity and contaminants, such as USP or NSF seals or ConsumerLab approval, is the main quality signal, since activity varies between products.
  • Reputable brands: ConsumerLab’s 2025 test covered Allergy Research Group, Arthur Andrew Medical, Doctor’s Best, Double Wood, NOW, Nutricost, Pure Encapsulations (NSK-SD), and Toku Flow; pass status per brand requires membership (ConsumerLab).
  • Formulation: Softgels and enteric-coated capsules are used to protect the enzyme from stomach acid; combination products may add vitamin K2, red yeast rice, or serrapeptase, which change the risk profile.
  • Soy origin: Nattokinase is made from soybeans; EU products must carry soy-allergen labeling (Commission Implementing Decision (EU) 2017/115), and non-GMO soy sourcing is commonly stated.

Practical Considerations

  • Time to effect: Laboratory clot-breakdown changes appear within 2–8 hours (Kurosawa 2015); blood pressure changes by 8 weeks (Kim 2008); carotid changes were reported only after 6–12 months at high doses (Ren 2017, Chen 2022).
  • Common pitfalls: Replacing prescribed anticoagulants; stacking several anticlotting supplements; assuming natto food equals vitamin K2-free capsules; comparing products by milligrams instead of FU; expecting cholesterol benefits at usual doses.
  • Regulatory status (US): Sold as a dietary supplement; the FDA (US Food and Drug Administration) does not approve dietary supplements before they are marketed (FDA Questions and Answers on Dietary Supplements).
  • Regulatory status (EU): One extract is an authorized novel food for adults, maximum 100 mg daily, excluding pregnancy and lactation, labeled for medical supervision with medication (Commission Implementing Decision (EU) 2017/115).
  • Cost and research incentives: Inexpensive and widely available. As an unpatentable supplement, its trials are small and often manufacturer-linked, and insurers have no incentive to fund outcome trials comparing it with costlier prescription anticoagulants, a structural gap in the evidence.

Interaction with Foundational Habits

  • Sleep: Direction: none known. No study links nattokinase to sleep disruption or improvement; an ongoing Taiwanese crossover trial is testing 6,000 FU daily on sleep quality in metabolic syndrome (clustered high blood pressure, blood sugar, waist size, and blood fats) (NCT07229521). Evening dosing has no reported effect on sleep.
  • Nutrition: Direction: potentiating for bleeding. Natto food supplies nattokinase plus vitamin K2; fish oil, garlic, and high-dose vitamin E add bleeding tendency. In warfarin users, swings in vitamin K intake alter warfarin’s effect. Taking capsules apart from protein-rich meals is common practice, untested.
  • Exercise: Direction: possibly potentiating (observational). Participants walking more than 5,000 steps daily had larger lipid and carotid improvements in the uncontrolled high-dose study (Chen 2022). Contact sports may raise bruising risk (theoretical). Muscle recovery is being studied (NCT07836634).
  • Stress management: Direction: none known. A single 2,000 FU dose did not change heart rate, cardiac output, or sympathetic (fight-or-flight) nerve activity in healthy men (Nara 2023); no study has examined cortisol.

Monitoring Protocol & Defining Success

Baseline testing before starting establishes bleeding safety and a reference point for expected changes. It includes a home or clinic blood pressure average, a complete blood count, and PT/INR and aPTT for anyone over 60, taking anticoagulant or antiplatelet drugs, or with a bleeding history; a lipid panel and fibrinogen are added when cholesterol or clotting tendency is the target.

Ongoing monitoring follows this cadence: blood pressure weekly for the first month, then every 3 months; clotting tests at 4 weeks and then every 3–6 months for people also on anticoagulant or antiplatelet drugs; complete blood count every 6–12 months; and lipids at 3 months, then every 6–12 months, on high-dose regimens. Success is a sustained blood pressure reduction without bleeding signs or adverse laboratory changes.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Blood pressure No established target for nattokinase use; track change from own baseline average Expected to change (modest fall when raised) Seated after 5 minutes’ rest, average of 2–3 readings; trials showed reductions only from systolic 130–159 mmHg (Kim 2008)
PT/INR 0.8–1.2 (standard reference range) Safety check: a rise signals bleeding risk Essential for warfarin users; no fasting needed; pair with aPTT
aPTT 25–35 seconds (standard reference range) Safety check: nattokinase prolonged it in a trial Laboratory-specific ranges vary; draw at a consistent time after dosing (Yoo 2019)
Hemoglobin Men 13.5–17.5 g/dL; women 12.0–15.5 g/dL (standard reference range) Safety check: a fall suggests hidden bleeding Part of the complete blood count; pair with platelets
Platelet count 150–450 × 10⁹/L (standard reference range) Safety check: low counts raise bleeding risk Part of the complete blood count; check before starting
LDL cholesterol No established target for nattokinase use; track change from own baseline Expected to change only at high doses Reported reductions at 10,800 FU without a control group (Chen 2022); fasting optional
Fibrinogen 200–400 mg/dL (standard reference range) Expected to change (modest fall) Fell 7–10% over 2 months in an uncontrolled study (Hsia 2009); raised by acute illness

Qualitative markers:

  • Bruising, gum bleeding, or nosebleeds (safety)
  • Heavier menstrual bleeding (safety)
  • Black stools or blood in urine (safety)
  • Sudden severe headache (safety, possible brain bleed)
  • Light-headedness on standing (excess blood pressure lowering)
  • Leg swelling or discomfort after long travel (circulation)

Emerging Research

  • Sleep and metabolic syndrome trial (ongoing): NCT07229521, 80 Taiwanese adults, blinded crossover, 6,000 FU daily for 12 weeks; primary outcomes sleep and cognition; completion February 2027. Positive: adds a sleep benefit. Null: reinforces no cognitive effect.
  • Inflammation in dyslipidemia (abnormal blood fats) trial (ongoing): NCT06183307, 48 adults in Brazil, 2,000 FU daily for 2 months versus placebo; primary outcome inflammatory status; completion December 2026. A positive result would add an anti-inflammatory benefit; a null result would narrow benefits to blood pressure.
  • Exercise muscle-damage pilot (completion date passed): NCT07836634, 14 participants in Taiwan, 2,000 FU for 28 days; registered completion 8 October 2026 has passed, the record still reads “active, not recruiting”, and no results are posted.
  • ICC-PACS cognition trial (completed): NCT05200234, registered completion December 2023, registry status “unknown”; results published: no global cognitive benefit at 8,000 FU (Zhang 2026), reflected in the thinking-skills benefit item.
  • NAPS (completed): NCT02080520, 265 adults, completed 2019; posted and published results were null for artery thickening, blood pressure, clotting factors, and cognition (Hodis 2021).
  • Dose-response gap: Positive uncontrolled high-dose data (Chen 2022) versus a null low-dose trial (Hodis 2021) leave a placebo-controlled high-dose trial, with bleeding outcomes, as the study most able to change current understanding.
  • Combination products: Nattokinase with red yeast rice outperformed nattokinase alone in coronary disease (Liu 2024) and beat placebo on cholesterol in dyslipidemia (Liu 2023), both co-authored by BYHEALTH staff; benefits may stem from red yeast rice’s monacolin K, chemically identical to the cholesterol drug lovastatin.
  • Microclots and long COVID: In laboratory microclot work, adding nattokinase gave little effect beyond ultrasound (Rasouli 2026), weakening the case for enzyme-based “microclot” regimens; spike-protein degradation remains a cell finding (Tanikawa 2022).
  • Bleeding safety with anticoagulant or antiplatelet drugs: No study has tested co-administration; a real-world series gave nattokinase only after anticoagulant courses (Gallelli 2021); controlled data on combining nattokinase with anticoagulants or antiplatelet drugs would strengthen or weaken its safety profile in older adults.

Conclusion

Nattokinase is a fermented-soybean enzyme sold as a supplement because it breaks down the protein mesh of blood clots. For health-focused adults weighing it long term, the human evidence is thin. The most consistent signal is a modest fall in blood pressure in people whose pressure is already raised; people with normal pressure saw no change in the longest study. One small study also found better recovery after stroke when added to rehabilitation. Claims that it shrinks artery plaque or lowers cholesterol rest on studies without proper comparison groups at several times the usual dose, while the longest study against placebo capsules found no slowing of artery thickening and no effect on thinking skills. No study has tested whether the purified enzyme prevents heart attacks, strokes, or early death; the longevity link comes from eating natto as food. Hopes that it clears Alzheimer-related or coronavirus proteins remain laboratory findings.

The main concern is bleeding. Controlled studies have not shown excess bleeding, but rare serious bleeds have occurred, with aspirin or with large amounts in very old age, and swapping a prescribed blood thinner for nattokinase has led to a dangerous clot. Pooled trials suggest a slight rise in blood sugar of unclear importance.

Much of the favorable research comes from manufacturers, supplement sellers, or groups working with them, while a prominent skeptical voice has advised makers of competing prescription drugs. Overall, the evidence is limited and the benefit-risk balance remains uncertain.

Top - Benefits - Risks - Protocol